

ACG2BUSA

REMARKS/ARGUMENTS

After entry of this paper, claims 15-32 are pending. Claims 33-56 are canceled herein, without prejudice, as being drawn to non-elected subject matter. Applicants reserve the right to prosecute the non-elected subject matter, including these non-elected claims, in a timely filed divisional application.

Restriction Requirement

The Examiner restricted the claims into the following groups:

<u>Group</u>	<u>Claims</u>
I	15-33, drawn to a method for treating using G17 peptide or fragment thereof;
II	34-55, drawn to a method for treating using antibodies; and
III	56, drawn to a composition.

As noted above, Applicants elected the claims of Group I, i.e., claims 15-33, drawn to a method for treating using G17 peptide or fragment thereof, without traverse.

Species Requirement

The Examiner asserted that the claims of Groups I-III are individually or dependently directed to a plurality of disclosed patentably distinct species of agent (see part (a) of claims 15, 34, or 56) used in combination with G17 peptide or with an antibody.

The Examiner required that Applicants elect a single disclosed species.

As noted above, Applicants elected the proton pump inhibitor as the agent. This election properly reads on elected claims 15-29, 31, and 32.

Applicants also request that upon finding the elected claims drawn to the proton pump inhibitor free from prior art, that the search be extended to cover claims drawn to the histamine receptor blocker agent.

ACG2BUSA

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account Number 08-3040.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9200
Telefacsimile: (215) 540-5818